| Year |
Citation |
Score |
| 2024 |
Naranjo NM, Kennedy A, Testa A, Verrillo CE, Altieri AD, Kean R, Hooper DC, Yu J, Zhao J, Abinader O, Pickles MW, Hawkins A, Kelly WK, Mitra R, Languino LR. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma. Cancer Biology & Therapy. 25: 2364433. PMID 38926911 DOI: 10.1080/15384047.2024.2364433 |
0.389 |
|
| 2023 |
Ferrari MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, Murugan P, Hahm E, Yu J, Kuzel TM, Gradilone SA, Mansini AP. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene. PMID 38135694 DOI: 10.1038/s41388-023-02925-x |
0.355 |
|
| 2023 |
Gritsina G, Fong KW, Lu X, Lin Z, Xie W, Agarwal S, Lin D, Schiltz GE, Beltran H, Corey E, Morrissey C, Wang Y, Zhao JC, Hussain M, Yu J. Chemokine receptor CXCR7 activates AURKA and promotes neuroendocrine prostate cancer growth. The Journal of Clinical Investigation. PMID 37347559 DOI: 10.1172/JCI166248 |
0.37 |
|
| 2023 |
Ferrari M, Wang L, Hoeppner L, Hahm E, Yu J, Kuzel T, Mansini A. Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target. Research Square. PMID 37333086 DOI: 10.21203/rs.3.rs-2968406/v1 |
0.324 |
|
| 2023 |
Lin Z, Agarwal S, Tan S, Shi H, Lu X, Tao Z, Dong X, Wu X, Zhao JC, Yu J. Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer. Oncogene. PMID 37198397 DOI: 10.1038/s41388-023-02718-2 |
0.461 |
|
| 2023 |
Xie W, Agarwal S, Yu J. Ferroptosis: the vulnerability within a cancer monster. The Journal of Clinical Investigation. 133. PMID 37183818 DOI: 10.1172/JCI170027 |
0.372 |
|
| 2023 |
Gritsina G, Yu J. CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene. PMID 36755058 DOI: 10.1038/s41388-023-02597-7 |
0.374 |
|
| 2022 |
Fong KW, Zhao JC, Lu X, Kim J, Piunti A, Shilatifard A, Yu J. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Molecular Cell. 82: 4611-4626.e7. PMID 36476474 DOI: 10.1016/j.molcel.2022.11.010 |
0.311 |
|
| 2022 |
Wang X, Brea L, Lu X, Gritsina G, Park SH, Xie W, Zhao JC, Yu J. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene. PMID 35931888 DOI: 10.1038/s41388-022-02423-6 |
0.4 |
|
| 2022 |
Lu X, Fong KW, Gritsina G, Wang F, Baca SC, Brea LT, Berchuck JE, Spisak S, Ross J, Morrissey C, Corey E, Chandel NS, Catalona WJ, Yang X, Freedman ML, ... ... Yu J, et al. HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nature Genetics. PMID 35468964 DOI: 10.1038/s41588-022-01045-8 |
0.41 |
|
| 2022 |
Rodríguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer. Cancer Research. PMID 35405009 DOI: 10.1158/0008-5472.CAN-21-3565 |
0.429 |
|
| 2021 |
Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene. PMID 34349243 DOI: 10.1038/s41388-021-01982-4 |
0.447 |
|
| 2021 |
Park SH, Fong KW, Kim J, Wang F, Lu X, Lee Y, Brea LT, Wadosky K, Guo C, Abdulkadir SA, Crispino JD, Fang D, Ntziachristos P, Liu X, Li X, ... ... Yu J, et al. Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science Advances. 7. PMID 33827814 DOI: 10.1126/sciadv.abe2261 |
0.368 |
|
| 2020 |
Martin MC, Zeng G, Yu J, Schiltz GE. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer. Journal of Medicinal Chemistry. PMID 33283516 DOI: 10.1021/acs.jmedchem.0c01344 |
0.318 |
|
| 2020 |
Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, ... ... Yu J, et al. Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Research. 80: 2072. PMID 32414837 DOI: 10.1158/0008-5472.Can-20-0768 |
0.346 |
|
| 2020 |
Numan Y, Zhao J, Tang S, Zhang Y, Zhang Q, Jovanovic B, VanderWeele DJ, Morgans AK, Cristofanilli M, Yu J, Hussain MHA. Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response. Journal of Clinical Oncology. 38: TPS275-TPS275. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps275 |
0.458 |
|
| 2019 |
Zhu S, Zhao D, Li C, Li Q, Jiang W, Liu Q, Wang R, Fazli L, Li Y, Zhang L, Yi Y, Meng Q, Wang W, Wang G, Zhang M, ... ... Yu J, et al. BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. Oncogene. PMID 31462713 DOI: 10.1038/S41388-019-0966-4 |
0.495 |
|
| 2019 |
Xu B, Song B, Lu X, Kim J, Hu M, Zhao JC, Yu J. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression. Cell Research. PMID 31324884 DOI: 10.1038/S41422-019-0204-1 |
0.48 |
|
| 2019 |
Berger A, Brady NJ, Bareja R, Robinson BD, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, ... Yu J, et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. The Journal of Clinical Investigation. 130. PMID 31260412 DOI: 10.1172/Jci127961 |
0.514 |
|
| 2019 |
Wang X, Brea LT, Yu J. Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy. American Journal of Clinical and Experimental Urology. 7: 85-91. PMID 31139703 |
0.33 |
|
| 2019 |
Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, ... ... Yu J, et al. Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer. Cancer Research. PMID 30952632 DOI: 10.1158/0008-5472.Can-18-2812 |
0.51 |
|
| 2019 |
Gritsina G, Gao WQ, Yu J. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. Asian Journal of Andrology. PMID 30950412 DOI: 10.4103/Aja.Aja_19_19 |
0.549 |
|
| 2019 |
Yu J, Li H, Zhang S, Wang A, Zhao Z, Liu X. Abstract P4-01-13: Molecular characterization of circulating tumor DNA in Chinese metastatic breast cancer (mBC) patients Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-01-13 |
0.363 |
|
| 2019 |
Berger A, Brady N, Bareja R, Robinson B, Conteduca V, Augello M, Puca L, Ahmed A, Lu X, Hwang I, Bagadion A, Sboner A, Elemento O, Paik J, Yu J, et al. Abstract 2099: N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2099 |
0.478 |
|
| 2018 |
Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Reports. 25: 2808-2820.e4. PMID 30517868 DOI: 10.1016/J.Celrep.2018.11.035 |
0.497 |
|
| 2018 |
Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, Yang YA, Sridhar S, Lu X, Abdulkadir SA, Vessella RL, Morrissey C, Kuzel TM, Catalona WJ, Yang XJ, ... Yu J, et al. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression. The Journal of Clinical Investigation. PMID 30511964 DOI: 10.1172/Jci122367 |
0.419 |
|
| 2018 |
Fong KW, Zhao JC, Song B, Zheng B, Yu J. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nature Communications. 9: 5007. PMID 30479348 DOI: 10.1038/S41467-018-07475-5 |
0.524 |
|
| 2018 |
Murmann AE, Yu J, Opal P, Peter ME. Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer. Trends in Cancer. 4: 684-700. PMID 30292352 DOI: 10.1016/J.Trecan.2018.08.004 |
0.396 |
|
| 2018 |
Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism. Blood. PMID 29844011 DOI: 10.1182/Blood-2017-10-811760 |
0.355 |
|
| 2018 |
Liu H, Dai X, Cao X, Yan H, Ji X, Zhang H, Shen S, Si Y, Zhang H, Chen J, Li L, Zhao JC, Yu J, Feng XH, Zhao B. PRDM4 mediates YAP-induced cell invasion by activating leukocyte-specific integrin β2 expression. Embo Reports. PMID 29669796 DOI: 10.15252/Embr.201745180 |
0.471 |
|
| 2018 |
Geng H, Bu HF, Liu F, Wu L, Pfeifer K, Chou PM, Wang X, Sun J, Lu L, Pandey A, Bartolomei MS, De Plaen IG, Wang P, Yu J, Qian J, et al. In Inflamed Intestinal Tissues and Epithelial Cells, Interleukin 22 Signaling Increases Expression of H19 Long Noncoding RNA, Which Promotes Mucosal Regeneration. Gastroenterology. PMID 29621481 DOI: 10.1053/J.Gastro.2018.03.058 |
0.305 |
|
| 2018 |
Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, Liu Q, Wang R, Xia B, Zhao JC, Song G, Mi W, Wang RF, Shi X, Lam HM, ... ... Yu J, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nature Communications. 9: 500. PMID 29402932 DOI: 10.1038/S41467-018-02863-3 |
0.537 |
|
| 2018 |
Li S, Fong K, Gritsina G, Zhang A, Zhao JC, Kim J, Yu J. Abstract 4886: Ligand-independent CXCR7 activation of MAPK signaling leads to prostate cancer enzalutamide resistance Cancer Research. 78: 4886-4886. DOI: 10.1158/1538-7445.Am2018-4886 |
0.46 |
|
| 2018 |
Fong K, Zhao J, Zheng B, Yu J. Abstract 1521: Role of Trim28 in prostate cancer Cancer Research. 78: 1521-1521. DOI: 10.1158/1538-7445.Am2018-1521 |
0.573 |
|
| 2018 |
Lee Y, Kim Ja, Changsheng Z, Lu X, Fong KW, Yu J. Abstract 1497: A PRC2 independent role of EZH2 in androgen receptor signaling in prostate cancer Cancer Research. 78: 1497-1497. DOI: 10.1158/1538-7445.Am2018-1497 |
0.543 |
|
| 2017 |
Wang L, Song G, Zhang X, Feng T, Pan J, Chen W, Yang M, Bai X, Pang Y, Yu J, Han J, Han B. PADI2-mediated citrullination promotes prostate cancer progression. Cancer Research. PMID 28819028 DOI: 10.1158/0008-5472.Can-17-0150 |
0.544 |
|
| 2017 |
Kim J, Jin H, Zhao JC, Yang YA, Li Y, Yang X, Dong X, Yu J. FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene. PMID 28319070 DOI: 10.1038/Onc.2017.50 |
0.499 |
|
| 2017 |
Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, ... ... Yu J, et al. CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Cell Reports. 18: 2373-2386. PMID 28273453 DOI: 10.1016/J.Celrep.2017.02.037 |
0.405 |
|
| 2017 |
Fong K, Zhao J, Kim J, Li S, Yang A, Song B, Rittié L, Hu M, Yang X, Perbal B, Yu J. Abstract 2080: Polycomb-mediated disruption of an AR-feedback loop drives castration-resistant prostate cancer Cancer Research. 77: 2080-2080. DOI: 10.1158/1538-7445.Am2017-2080 |
0.556 |
|
| 2016 |
Fong KW, Zhao JC, Kim J, Li S, Yang YA, Song B, Rittié L, Hu M, Yang XJ, Perbal B, Yu J. Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer. Cancer Research. PMID 27815387 DOI: 10.1158/0008-5472.Can-16-1949 |
0.52 |
|
| 2016 |
Kim JY, Yu J, Abdulkadir SA, Chakravarti D. KAT8 regulates androgen signaling in prostate cancer cells. Molecular Endocrinology (Baltimore, Md.). me20161024. PMID 27268279 DOI: 10.1210/Me.2016-1024 |
0.543 |
|
| 2016 |
Yang YA, Zhao JC, Fong KW, Kim J, Li S, Song C, Song B, Zheng B, He C, Yu J. FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function. Nucleic Acids Research. PMID 27257062 DOI: 10.1093/Nar/Gkw498 |
0.355 |
|
| 2016 |
Zhao J, Li X, Guo M, Yu J, Yan C. The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation. Bmc Genomics. 17: 335. PMID 27146783 DOI: 10.1186/S12864-016-2664-8 |
0.36 |
|
| 2016 |
Zhao JC, Fong KW, Jin HJ, Yang YA, Kim J, Yu J. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene. PMID 26751772 DOI: 10.1038/Onc.2015.496 |
0.522 |
|
| 2016 |
Kim J, Jin H, Zhao J, Parimi V, Yang X, Yu J. Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation Cancer Research. 76: 1801-1801. DOI: 10.1158/1538-7445.Am2016-1801 |
0.538 |
|
| 2015 |
Wang L, Song G, Tan W, Qi M, Zhang L, Chan J, Yu J, Han J, Han B. miR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Oncotarget. PMID 26451614 DOI: 10.18632/Oncotarget.5427 |
0.341 |
|
| 2015 |
Zhang A, Zhao JC, Kim J, Fong KW, Yang YA, Chakravarti D, Mo YY, Yu J. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Reports. PMID 26411689 DOI: 10.1016/J.Celrep.2015.08.069 |
0.52 |
|
| 2015 |
Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC, Yu J. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. PMID 26364613 DOI: 10.1038/Onc.2015.340 |
0.352 |
|
| 2015 |
Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes & Diseases. 2: 144-151. PMID 26114156 DOI: 10.1016/J.Gendis.2015.01.003 |
0.491 |
|
| 2014 |
Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Qi M, Yu J, Han B. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. Oncogene. PMID 25500540 DOI: 10.1038/Onc.2014.401 |
0.507 |
|
| 2014 |
Yang YA, Kim J, Yu J. Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer. The Application of Clinical Genetics. 7: 81-91. PMID 24876790 DOI: 10.2147/Tacg.S35598 |
0.491 |
|
| 2014 |
Jin HJ, Zhao JC, Wu L, Kim J, Yu J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nature Communications. 5: 3972. PMID 24875621 DOI: 10.1038/Ncomms4972 |
0.366 |
|
| 2014 |
Kim J, Wu L, Zhao JC, Jin H, Yu J. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c Oncogene. 33: 5183-5192. PMID 24186205 DOI: 10.1038/Onc.2013.461 |
0.354 |
|
| 2013 |
Jin HJ, Kim J, Yu J. Androgen receptor genomic regulation. Translational Andrology and Urology. 2: 157-177. PMID 25237629 DOI: 10.3978/J.Issn.2223-4683.2013.09.01 |
0.478 |
|
| 2013 |
Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Research. 73: 6068-79. PMID 23913826 DOI: 10.1158/0008-5472.Can-13-0882 |
0.542 |
|
| 2013 |
Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein & Cell. 4: 331-41. PMID 23636686 DOI: 10.1007/S13238-013-2093-2 |
0.509 |
|
| 2013 |
Wang L, Zeng X, Chen S, Ding L, Zhong J, Zhao JC, Wang L, Sarver A, Koller A, Zhi J, Ma Y, Yu J, Chen J, Huang H. BRCA1 is a negative modulator of the PRC2 complex. The Embo Journal. 32: 1584-97. PMID 23624935 DOI: 10.1038/Emboj.2013.95 |
0.398 |
|
| 2013 |
Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Research. 73: 3725-36. PMID 23539448 DOI: 10.1158/0008-5472.Can-12-3468 |
0.543 |
|
| 2013 |
Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will C, Neri A, Kelleher NL, Yu J, Licht JD. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene. 32: 2882-90. PMID 22797064 DOI: 10.1038/Onc.2012.297 |
0.507 |
|
| 2013 |
Kim J, Wu L, Jin H, Zhao J, Yu J. Abstract 3077: TMPRSS2-ERG regulation of miRNA in prostate cancer. Cancer Research. 73: 3077-3077. DOI: 10.1158/1538-7445.Am2013-3077 |
0.416 |
|
| 2013 |
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, et al. Correction: Corrigendum: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature. 499: 504-504. DOI: 10.1038/Nature12288 |
0.389 |
|
| 2013 |
Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, et al. Erratum to Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer [Cancer Cell, 19 (2011) 664-678] Cancer Cell. 23. DOI: 10.1016/J.Ccr.2013.04.005 |
0.51 |
|
| 2012 |
Kim J, Yu J. Interrogating genomic and epigenomic data to understand prostate cancer. Biochimica Et Biophysica Acta. 1825: 186-96. PMID 22240201 DOI: 10.1016/J.Bbcan.2011.12.003 |
0.462 |
|
| 2012 |
Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes & Development. 26: 54-68. PMID 22215811 DOI: 10.1101/Gad.173435.111 |
0.445 |
|
| 2012 |
Zhao JC, Yu J, Runkle C, Wu L, Hu M, Wu D, Liu JS, Wang Q, Qin ZS, Yu J. Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Research. 22: 322-31. PMID 22179855 DOI: 10.1101/Gr.131508.111 |
0.545 |
|
| 2012 |
Zhao JC, Runkle C, Yu J, Wu L, Jin H, Kuzel T, Lee C, Yu J. Abstract IA19: Cooperation between androgen receptor and Polycomb in prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-Ia19 |
0.572 |
|
| 2012 |
Zhao J, Runkle C, Wu L, Jin H, Yu J. Abstract LB-273: Transcriptional regulation by androgen receptor in prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-273 |
0.583 |
|
| 2011 |
Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM, Zynger DL, Eeckhoute J, Yu J, Luo J, Brown M, Clinton SK, Nephew KP, Huang TH, Li W, et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Research. 71: 6738-48. PMID 21900400 DOI: 10.1158/0008-5472.Can-11-1882 |
0.47 |
|
| 2011 |
Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, ... ... Yu J, et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 20: 187-99. PMID 21840484 DOI: 10.1016/J.Ccr.2011.06.016 |
0.387 |
|
| 2011 |
Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, ... ... Yu J, et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Research. 21: 1028-41. PMID 21724842 DOI: 10.1101/Gr.119347.110 |
0.437 |
|
| 2011 |
Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 19: 664-78. PMID 21575865 DOI: 10.1016/J.Ccr.2011.04.010 |
0.457 |
|
| 2011 |
Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R, Markovitz DM. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes & Development. 25: 673-8. PMID 21460035 DOI: 10.1101/Gad.2036411 |
0.342 |
|
| 2011 |
Corey SJ, Yu J. Cancer cell migration: when red light switched to green. Asian Journal of Andrology. 13: 177-8. PMID 21240294 DOI: 10.1038/Aja.2010.176 |
0.396 |
|
| 2011 |
Brenner JC, Ateeq B, Li Y, Yocum A, Cao Q, Asangani I, Patel S, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Wang X, Cao X, Mehra R, et al. Abstract 953: Mechanistic rationale for inhibition of Poly(ADP-Ribose) Polymerase in ETS gene fusion positive prostate cancer Cancer Research. 71: 953-953. DOI: 10.1158/1538-7445.Am2011-953 |
0.535 |
|
| 2011 |
Dhanasekaran SM, Kim J(H, Prensner J, Cao X, Robinson D, Kalyana-Sundaram S, Shankar S, Jing X, Iyer M, Sam L, Hu M, Grasso C, Maher C, Palanisamy N, Mehra R, ... ... Yu J, et al. Abstract 4840: DNA methylation patterns and transcript isoform regulation in prostate cancer Cancer Research. 71: 4840-4840. DOI: 10.1158/1538-7445.Am2011-4840 |
0.409 |
|
| 2011 |
Cao Q, Mani R, Ateeq B, Dhanasekaren SM, Asangani I, Yu J, Prensner J, Kim JJ, Brenner JC, Cao X, Jing X, Wang R, Li Y, Dahiya A, Wang L, et al. Abstract 2795: An onco-protein axis linking polycomb repressive complex 2 and polycomb repressive complex 1 through miRNAs in cancer Cancer Research. 71: 2795-2795. DOI: 10.1158/1538-7445.Am2011-2795 |
0.465 |
|
| 2011 |
Mani RS, Tomlins SA, Brenner CJ, Wang L, Iyer M, Yu J, Cao Q, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Abstract 2155: The origins and functional consequences of ETS gene fusions in prostate cancer Cancer Research. 71: 2155-2155. DOI: 10.1158/1538-7445.Am2011-2155 |
0.554 |
|
| 2010 |
Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (New York, N.Y.). 12: 1031-40. PMID 21170267 DOI: 10.1593/Neo.10866 |
0.561 |
|
| 2010 |
Pichot CS, Arvanitis C, Hartig SM, Jensen SA, Bechill J, Marzouk S, Yu J, Frost JA, Corey SJ. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-WASp. Cancer Research. 70: 8347-56. PMID 20940394 DOI: 10.1158/0008-5472.Can-09-4149 |
0.354 |
|
| 2010 |
Yu J, Cao Q, Yu J, Wu L, Dallol A, Li J, Chen G, Grasso C, Cao X, Lonigro RJ, Varambally S, Mehra R, Palanisamy N, Wu JY, Latif F, et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene. 29: 5370-80. PMID 20622896 DOI: 10.1038/Onc.2010.269 |
0.529 |
|
| 2010 |
Qin ZS, Yu J, Shen J, Maher CA, Hu M, Kalyana-Sundaram S, Yu J, Chinnaiyan AM. HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. Bmc Bioinformatics. 11: 369. PMID 20598134 DOI: 10.1186/1471-2105-11-369 |
0.314 |
|
| 2010 |
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. European Urology. 58: e29-30; author reply. PMID 20537788 DOI: 10.1016/J.Eururo.2010.05.003 |
0.41 |
|
| 2010 |
Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, Ding S, Guan KL. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes & Development. 24: 1106-18. PMID 20516196 DOI: 10.1101/Gad.1903310 |
0.36 |
|
| 2010 |
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 17: 443-54. PMID 20478527 DOI: 10.1016/J.Ccr.2010.03.018 |
0.554 |
|
| 2010 |
Rickman DS, Chen Y, Banerjee S, Pan Y, Moss B, Sboner A, Yu J, Perner S, Lafargue C, VanDoren V, Mertz K, Setlur S, Sircar K, Gerstein M, Chinnaiyan A, et al. Abstract LB-21: Emergence of castration resistant prostate cancer class defined by recurrentERGfusion Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-21 |
0.559 |
|
| 2009 |
Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran T, Yu J, Varambally S, Li Y, Omenn GS, Chinnaiyan AM, Nesvizhskii AI. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. Plos One. 4: e7075. PMID 19763266 DOI: 10.1371/Journal.Pone.0007075 |
0.497 |
|
| 2009 |
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138: 245-56. PMID 19632176 DOI: 10.1016/J.Cell.2009.04.056 |
0.534 |
|
| 2009 |
Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, Lonigro RJ, Schroth G, Kumar-Sinha C, Chinnaiyan AM. Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America. 106: 12353-8. PMID 19592507 DOI: 10.1073/Pnas.0904720106 |
0.405 |
|
| 2009 |
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 457: 910-4. PMID 19212411 DOI: 10.1038/Nature07762 |
0.522 |
|
| 2009 |
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, et al. Tomlins et al. reply Nature. 457. DOI: 10.1038/Nature07739 |
0.445 |
|
| 2008 |
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (New York, N.Y.). 322: 1695-9. PMID 19008416 DOI: 10.1126/Science.1165395 |
0.467 |
|
| 2008 |
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 27: 7274-84. PMID 18806826 DOI: 10.1038/Onc.2008.333 |
0.44 |
|
| 2008 |
Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Research. 68: 7629-37. PMID 18794152 DOI: 10.1158/0008-5472.Can-08-2014 |
0.514 |
|
| 2008 |
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes & Development. 22: 1962-71. PMID 18579750 DOI: 10.1101/Gad.1664408 |
0.419 |
|
| 2008 |
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (New York, N.Y.). 10: 177-88. PMID 18283340 DOI: 10.1593/Neo.07822 |
0.547 |
|
| 2008 |
Yu J, Yu J, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, Lippman ME. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia (New York, N.Y.). 10: 79-88. PMID 18231641 DOI: 10.1593/Neo.07859 |
0.362 |
|
| 2007 |
Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Research. 67: 10657-63. PMID 18006806 DOI: 10.1158/0008-5472.Can-07-2498 |
0.528 |
|
| 2007 |
Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 12: 419-31. PMID 17996646 DOI: 10.1016/J.Ccr.2007.10.016 |
0.485 |
|
| 2007 |
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & Development. 21: 2747-61. PMID 17974916 DOI: 10.1101/Gad.1602907 |
0.418 |
|
| 2007 |
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 448: 595-9. PMID 17671502 DOI: 10.1038/Nature06024 |
0.531 |
|
| 2007 |
Yu J, Yu J, Almal AA, Dhanasekaran SM, Ghosh D, Worzel WP, Chinnaiyan AM. Feature selection and molecular classification of cancer using genetic programming. Neoplasia (New York, N.Y.). 9: 292-303. PMID 17460773 DOI: 10.1593/Neo.07121 |
0.377 |
|
| 2004 |
Yu J, He S, Friedman JS, Akimoto M, Ghosh D, Mears AJ, Hicks D, Swaroop A. Altered expression of genes of the Bmp/Smad and Wnt/calcium signaling pathways in the cone-only Nrl-/- mouse retina, revealed by gene profiling using custom cDNA microarrays. The Journal of Biological Chemistry. 279: 42211-20. PMID 15292180 DOI: 10.1074/Jbc.M408223200 |
0.523 |
|
| 2004 |
Yu J, Mears AJ, Yoshida S, Farjo R, Carter TA, Ghosh D, Hero A, Barlow C, Swaroop A. From disease genes to cellular pathways: a progress report. Novartis Foundation Symposium. 255: 147-60; discussion 1. PMID 14750602 DOI: 10.1002/0470092645.Ch11 |
0.514 |
|
| 2003 |
Yu J, Farjo R, MacNee SP, Baehr W, Stambolian DE, Swaroop A. Annotation and analysis of 10,000 expressed sequence tags from developing mouse eye and adult retina. Genome Biology. 4: R65. PMID 14519200 DOI: 10.1186/Gb-2003-4-10-R65 |
0.518 |
|
| 2002 |
Yu J, Othman MI, Farjo R, Zareparsi S, MacNee SP, Yoshida S, Swaroop A. Evaluation and optimization of procedures for target labeling and hybridization of cDNA microarrays. Molecular Vision. 8: 130-7. PMID 12011805 |
0.399 |
|
| 2002 |
Farjo R, Yu J, Othman MI, Yoshida S, Sheth S, Glaser T, Baehr W, Swaroop A. Mouse eye gene microarrays for investigating ocular development and disease. Vision Research. 42: 463-70. PMID 11853762 DOI: 10.1016/S0042-6989(01)00219-X |
0.499 |
|
| Show low-probability matches. |